CAPR → $60.00 by Sep 16, 2026.

CAPR: A Biotech with Enormous Potential in 2026 This isn’t financial advice, just my own DD. Disclaimer: I have a long position in CAPR ($10.69 average) TLDR: CAPR has FDA approval decision for their drug, Deramiocel, on August 22nd, 2026. I think their phase 3 data looks fantastic and has a strong chance of being approved. If it is approved, I predict that this stock will be trading around $60 per share (over $70 per share if given a broad …